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Abstract
Background:  Cholesterol homeostasis and xenobiotic metabolism are complex biological
processes, which are difficult to study with traditional methods. Deciphering complex regulation
and response of these two processes to different factors is crucial also for understanding of disease
development. Systems biology tools as are microarrays can importantly contribute to this
knowledge and can also discover novel interactions between the two processes.
Results: We have developed a low density Sterolgene v0 cDNA microarray dedicated to studies
of cholesterol homeostasis and drug metabolism in the mouse. To illustrate its performance, we
have analyzed mouse liver samples from studies focused on regulation of cholesterol homeostasis
and drug metabolism by diet, drugs and inflammation. We observed down-regulation of cholesterol
biosynthesis during fasting and high-cholesterol diet and subsequent up-regulation by inflammation.
Drug metabolism was down-regulated by fasting and inflammation, but up-regulated by
phenobarbital treatment and high-cholesterol diet. Additionally, the performance of the Sterolgene
v0 was compared to the two commercial high density microarray platforms: the Agilent cDNA
(G4104A) and the Affymetrix MOE430A GeneChip. We hybridized identical RNA samples to the
commercial microarrays and showed that the performance of Sterolgene is comparable to
commercial arrays in terms of detection of changes in cholesterol homeostasis and drug
metabolism.
Conclusion: Using the Sterolgene v0 microarray we were able to detect important changes in
cholesterol homeostasis and drug metabolism caused by diet, drugs and inflammation. Together
with its next generations the Sterolgene microarrays represent original and dedicated tools
enabling focused and cost effective studies of cholesterol homeostasis and drug metabolism. These
microarrays have the potential of being further developed into screening or diagnostic tools.
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Background
The level of cholesterol in mammals is tightly regulated by
multiple homeostatic mechanisms which affect choles-
terol biosynthesis, metabolism and uptake-excretion
cycles. This regulation is achieved by different transcrip-
tional factors, including sterol regulatory element-binding
proteins (SREBP) and different members of the nuclear
receptor superfamily [1,2]. Under certain conditions
(inflammation, high-cholesterol diet, etc.) cholesterol
homeostasis is disrupted and can lead to atherosclerosis
and other cardiovascular diseases, gallstone formation or
neurological disorders. Cardiovascular diseases remain a
leading cause of death in the developed world and are
therefore an important research area. The central question
is how different physiological processes being provoked
by endogenous and exogenous sources influence choles-
terol homeostasis and what the key targets of these regu-
lations are. These findings are also of crucial importance
for the development of novel hypolipidemic drugs.
Each exogenous compound entering the body requires
detoxification by drug metabolism enzymes from differ-
ent families. This process is also regulated by members of
the nuclear receptor superfamily [3]. Recent studies have
shown important crosstalk between drug metabolism and
cholesterol homeostasis through nuclear receptor-medi-
ated pathways [4]. However, this complex regulatory net-
work is still far from being completely understood.
Microarray technology is a powerful tool and has gained
broad usage in basic and medical research. It enables sys-
temic studies of gene expression of selected genes or of the
entire genome and can lead to the discovery of new genes
involved in biological processes. Several commercial and
academic DNA microarrays are currently available. Com-
mercially available are often whole-genome arrays, which
are not cost-effective for studies of a small number of
selected genes [5]. This provides a rationale for developing
small-scale arrays, enabling cost-effective studies of a lim-
ited number of genes involved in specific biochemical
pathways [6-9], thus allowing more detailed studies of
specific biological processes. Commercial arrays often do
not include genes which may be of a particular interest to
specific users [10-12]; neither do they always offer control
over probe sequences. In the development process of a
small-scale custom array special care is taken in the selec-
tion of the studied genes and specifically the position of
their probes. The rationale for designing custom arrays is
in the ease of their adaptation, e.g. addition of new genes/
probes, removal of non-working probes and modification
of the geometry. Owing to low production costs and small
overhead with annotations the adaptations can be per-
formed on the fly during experimentation, which is unfor-
tunately still not the case with commercially available
arrays.
We have developed Sterolgene v0 cDNA microarray as a
prototype in a series of Sterolgene/Steroltalk cDNA micro-
arrays. These dedicated arrays enable focused studies of
cholesterol homeostasis and drug metabolism in mouse
and in human. We have validated the Sterolgene array in
studies of experimental disturbances of cholesterol home-
ostasis by inflammation, diet and drugs in the mouse
liver. We compared the results to two commercial plat-
forms: the Agilent cDNA (G4104A) and the Affymetrix
MOE430A GeneChip. Within this paper we show that the
Sterolgene array performs as well as any of the two com-
mercial platforms in terms of detection of changes in
expression of genes of our interest from the cholesterol
homeostasis and drug metabolism induced by the studied
factors.
Results
Production of the Sterolgene v0 microarray
The Sterolgene array contains 95 mouse genes known to
be involved in cholesterol homeostasis and drug metabo-
lism. Among these are members of the cytochrome P450
superfamily, the nuclear receptor superfamily, the ABC
transporters and other transporter families, genes for cho-
lesterol biosynthesis and SREBP signaling and some other
genes linked to cholesterol homeostasis (Figure 1). The
complete gene list with corresponding accession numbers
is available in Additional file 1. The positions of probes
have been selected according to a priori knowledge of each
gene. Probes detect all gene transcripts known at the time
of design. In case of major differences between transcripts
more probes per gene were selected. Each gene probe is
spotted in 6 replicas, three in two blocks. Each block con-
tains 23 types of positive controls (most of them spotted
in 6 replicas) and 3 types of negative controls (Figure 2).
These serve as control of quality; positive controls are also
used for data normalization. Level of unspecific cross-
hybridization, background intensity and uniformity were
used to optimize hybridization and washing protocols.
Normalization of Sterolgene data
Normalization of Sterolgene data was done using LOW-
ESS fit to normalization spike in RNAs according to their
average intensity (A = log2√(R*G), where R and G repre-
sent signal intensities). Figure 3A shows a MA plot of Ster-
olgene data and a LOWESS curve fitted to the
normalization controls. However, data from normaliza-
tion controls were first adjusted according to concentra-
tions in which normalization RNAs are added to sample
RNAs: log2 ratios of concentrations are subtracted from
the log2 ratios of measured intensities (M = log2(R/G)). In
Figure 3C the same data as in 3A is shown but with nor-
malization controls adjusted according to their RNA con-
centrations. Notice the difference between the
normalization curves at large A values. Such adjustment
results in better fit of the normalization curve and conse-BMC Genomics 2008, 9:76 http://www.biomedcentral.com/1471-2164/9/76
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quently in more accurate normalization. Figures 3B and
3D show MA plots of data normalized according to the
LOWESS curves shown in Figures 3A and 3C, respectively.
Notice the difference in M for genes with large A values.
Sterolgene data was normalized in Orange software [13]
using a dedicated normalization widget, which was devel-
oped specifically for normalization of custom low-density
arrays.
Acute TNFα inflammation and fasting affect cholesterol 
homeostasis and drug metabolism
The Sterolgene microarray was first evaluated in studies of
how acute inflammation affects cholesterol homeostasis
and drug metabolism. Mouse liver RNAs from the fasting
and TNF-α/fasted experiments were hybridized to Agilent
10 K cDNA microarrays (G4104A) and Sterolgene arrays
according to the recommended protocols. Differential
expression was determined by two tailed Student's t-test.
For Sterolgene data, probability of type I error αS = 0.05
was used. For Agilent data, a complementary probability
of type I error was calculated according to Bonferroni cor-
rection for multiple testing (αA =  αS*nS/nA = 0.00055
where nS and nA represent the number of genes included
in Sterolgene and Agilent arrays, respectively), but final
analysis was made using a more relaxed criteria αA = 0.01.
Using the Sterolgene array we show that fasting turns off
most of anabolic processes due to energy conserving shifts
in the liver and we observe a down-regulation of a major-
ity of genes. These genes code for drug metabolizing
enzymes (Cyp3a41,  Cyp1a2,  and Cyp3a25), different
nuclear receptors (Pparα, Rorγ, Rorα, and Lxrα), choles-
terol biosynthesis (Acat2, Mvk, Sc4mol, Cyp51a1, Nsdhl,
Sc5d,) and transcriptional regulation of cholesterol bio-
synthesis (Srebp2) (Table 1). We also observed down-reg-
ulation of Alas1 (delta-aminolevulinate synthase 1) and
Cyp11a1, which has previously been reported [14]. How-
ever, bile acid synthesis (Cyp8b1) is up-regulated by fast-
ing. Three down-regulated (Cyp51a1, Sc4mol, Srebp2) and
one up-regulated (Cyp8b1) gene were confirmed by RT-
PCR [15] (Figure 4A).
In TNF-α treated fasted mice we observe up-regulation of
cholesterol biosynthesis (Cyp51a1, Sc4mol) and down-reg-
ulation of cholesterol excretion (Cyp8b1) (Table 2). How-
ever, drug metabolism is further repressed (Cyp2f2,
Cyp2j5, Cyp3a25) and this also has previously been shown
[16]. Two up-regulated (Cyp51a1, Sc4mol) and one down-
regulated gene (Cyp8b1) from cholesterol homeostasis
have been confirmed by RT-PCR [15] (Figure 4B).
Drug metabolism and cholesterol homeostasis Figure 1
Drug metabolism and cholesterol homeostasis. Main groups of genes involved in cholesterol homeostasis and drug 
metabolism present on the Sterolgene v0 cDNA microarray. A scheme of the liver cell is shown together with its surroundings 
(blood, bile).
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With the Agilent array we were not able to detect any
change in cholesterol homeostasis and drug metabolism
caused by TNF-α and fasting (Additional files 2 and 3).
Agreement between both platforms is low with only one
gene in common in TNF-α/fasted experiment (Cyp2f2)
and with no genes in common in fasting experiment.
Additionally, we have selected only genes that are present
in both platforms (we found 54 such genes) and deter-
mined their differential expression using the same p-value
cut-off as for Sterolgene data (α = 0.05). The rationale
behind was not to tighten the analysis conditions for Agi-
lent data just due to the fact that the Agilent array contains
more genes than the Sterolgene array. In fasting experi-
ment we found 5 genes differentially expressed (Addi-
tional file 4) and of these Cyp1a2  was confirmed by
Sterolgene and RT-PCR, Actb by RT-PCR, while Apoa1 was
not confirmed by RT-PCR [15] (Figure 4A). In TNF-α/
fasted experiment we found 4 genes differentially
expressed (Additional file 5) and of these Cyp2f2 was con-
firmed by the Sterolgene (RT-PCR not performed), and
Actb and Apoa1 by RT-PCR [15].
Low correspondence in differential expression may be due
to the fact that of 54 genes in common only 20 showed
significant signal on the Agilent arrays. For these genes we
calculated Pearson's product moment correlation coeffi-
cient between log2 ratios in both experiments. Figure 5A
shows a scatterplot of that data. Though the correspond-
ence in differential expression is low, we observed a signif-
icant correlation between the platforms (r = 0.508, p =
0.001, N = 40), which is comparable to correlations
reported by other cross-platform comparison studies
[12,17-19].
Phenobarbital and cholesterol feeding affect cholesterol 
homeostasis and drug metabolism
The Sterolgene array was also tested in studies of how phe-
nobarbital and cholesterol feeding affect cholesterol
homeostasis and drug metabolism. Mouse liver RNAs
were hybridized to Affymetrix MOE430A GeneChips and
Sterolgene arrays according to the recommended proto-
cols. Differential expression was determined by two tailed
Student's t-test. For Sterolgene data, probability of type I
error αS = 0.1 was used. For Affymetrix data, a comple-
mentary probability of type I error was calculated accord-
ing to Bonferroni correction for multiple testing (αAf =
αS*nS/nAf  = 0.00043 where nS  and nAf  represent the
number of genes included in Sterolgene and Affymetrix
arrays, respectively), but final analysis was made using a
more relaxed criteria αA = 0.001.
In phenobarbital experiment, we detected several previ-
ously known up-regulated genes (Cyp2b and Cyp3a fami-
lies, Cyp2a4 and Alas1) [20-22] using the Sterolgene array
(Table 3). However, among these only Cyp2b10  was
detected using Affymetrix arrays (Additional file 6). Alas1,
Cyp2b10 and Cyp3a11 were confirmed by RT-PCR (Figure
4C).
In cholesterol feeding experiment, we detected down-reg-
ulation of the cholesterol biosynthesis (Fdft1,  Sqle,
Cyp51a1, Nsdhl) on both platforms (Table 4 and Addi-
tional file 7). However, with Sterolgene we additionally
detected up-regulation of the following genes: drug-
metabolizing enzyme gene Cyp3a11 and nuclear receptor
Shp (Nr0b2, small heterodimeric partner) as has been pre-
viously shown [23,24], cholesterol transporter Scp2
(Sterol carrier protein 2), and Ldlrap1 (LDL receptor adap-
tor protein 1). Cyp3a11 and Fdft1 were confirmed by RT-
PCR (Figure 4D).
Additionally, we have selected only genes that are present
in both platforms (we found 92 such genes) and deter-
mined their differential expression using the same p-value
cut-off as for Sterolgene data (α = 0.1), with the same
rationale as for the analysis of Agilent data. In phenobar-
bital experiment we found 21 genes differentially
Sterolgene v0 microarray design Figure 2
Sterolgene v0 microarray design. Complete array con-
taining 12 blocks was spotted twice to increase number of 
replicas. Each block contains positive and negative controls 
to enable spatial normalization. Each gene probe is spotted 
three times in two blocks. Green spots – positive controls: L 
– Firefly luciferase, A – ArrayControls Spikes (Ambion); 
white spots – negative controls: C – bacterial gene probe, SB 
– spotting buffer, N – empty spot; grey spots – salmon sperm 
DNA (S); yellow spots – gene probes (G).
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expressed (Additional file 8) and of these Alas1  and
Cyp2b10  were confirmed by Sterolgene and RT-PCR,
Cyp2a4 and Nr2c1 by Sterolgene (RT-PCR not performed),
Scap by RT-PCR, while for Apoa1 and Scarb1 no confirma-
tion was found (Figure 4C).
In cholesterol feeding experiment we found 41 genes dif-
ferentially expressed (Additional file 9) and of these Fdft1
was confirmed by Sterolgene and RT-PCR, Acss2, Cyp51a1,
Nsdhl,  Pmvk  and  Sqle  by Sterolgene (RT-PCR not per-
formed), Cyp26a1 by RT-PCR, while for Ppara and Scap no
confirmation was found (Figure 4D).
Normalization of Sterolgene v0 microarray data Figure 3
Normalization of Sterolgene v0 microarray data. MA plots of Sterolgene v0 microarray data illustrating its normaliza-
tion. Genes are marked with crosses (+), Ambion ArrayControl spikes with circles ( ) and diamonds (), and Firefly luciferase 
mRNAs with squares (). A: data before normalization together with LOWESS curve through normalization spike in RNAs. C: 
the same data as shown in A, but with normalization controls adjusted according to their RNA concentrations (see text for 
details). B and D: data after normalization according to LOWESS curves shown in A and C, respectively. Adjusted are 4 types 
of Ambion spikes marked with green, orange and red circles/diamonds.
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From the 92 genes that are present in both platforms we
selected those that showed signal on both platforms and
calculated a Pearson's product moment correlation coeffi-
cient between log2 ratios for data from both experiments.
Figure 5B shows scatterplot of that data. We observed a
similar correlation as for the Agilent-Steroltalk compari-
son (r = 0.499, p = 0.000, N = 319) and comparable to cor-
relations reported by other cross-platform comparison
studies [12,17-19]. Since more probes per gene are availa-
ble on Affymetrix array we included all in the correlation
analysis.
Discussion
Systemic studies of cholesterol homeostasis and drug
metabolism are still limited. In order to promote the
implementation of systems biology approaches to this
two research areas, we have developed the Sterolgene
array. It is a highly customizable tool that together with its
human version allows for detailed studies of the two bio-
logical processes in mouse and in human. The main goal
of this study was to evaluate the performance of the Ster-
olgene array in typical studies of cholesterol homeostasis
and drug metabolism in comparison with two commer-
cial platforms (Agilent and Affymetrix). Several recent
papers discuss the comparative data between different
microarrays platforms [12,17-19,25]. Many of these stud-
ies calculated different correlation coefficients, measured
reproducibility, but some have also taken into considera-
tion the biological aspects of the comparison [12,19,26].
This approach was also undertaken in our evaluations of
the performance of the Sterolgene array.
We have selected different factors, such as diet, drug treat-
ment and inflammation, where scattered information
existed about their effect on cholesterol homeostasis and
drug metabolism (Figure 6). We analyzed the data as it is
Table 1: Differentially expressed genes in the mouse liver after fasting (Sterolgene v0 microarray). Differentially expressed genes in 
the mouse liver after fasting as detected by the Sterolgene array (α = 0.05). 
Gene name and function Gene symbol Log2 ratio GeneBank Acc. No.
Cholesterol biosynthesis
Acetyl-CoA acetyltransferase 2 Acat2 -1.13 NM_009338
Mevalonate kinase Mvk -0.56 NM_023556
Lanosterol 14α-demethylase Cyp51a1 -1.32 BC031813
Sterol-C4-methyl oxidase-like Sc4mol -2.05 NM_025436
NAD(P) dependent steroid Nsdhl -1.47 BC019945
dehydrogenase-like
Sterol C5 desaturase Sc5d -1.75 BC024132
Bile acid biosynthesis
Sterol 12α-hydroxylase Cyp8b1 0.49 NM_010012
Cytochrome P450 superfamily
Cytochrome P450, 1a2 Cyp1a2 -1.35 NM_009993
Cytochrome P450, 3a25 Cyp3a25 -0.78 BC028855
Cytochrome P450, 3a41 Cyp3a41 -1.91 NM_017396
Cholesterol side chain cleavage enzyme Cyp11a1 0.41 NM_019779
Retionic acid hydrolase Cyp26a1 -0.83 NM_007811
Nuclear receptor superfamily
Peroxisome proliferator-activated Nr1c1 -1.03 NM_011144
receptor alpha
Retinoic acid-related orphan Nr1f3 -0.60 NM_011281
receptor gamma
Retinoic acid-related orphan Nr1f1 -0.54 NM_013646
receptor alpha
Liver X receptor beta Nr1h2 -0.46 NM_009473
Constitutive androstane receptor Nr1i3 0.22 NM_009803
Transcription factors
Sterol regulatory element binding transcription factor 2 Srebp2 -0.60 NM_033218
CCAAT/enhancer binding protein alpha Cebpa -0.38 BC028890
Transcription factor 1 Tcf1 0.17 NM_009327
Other
Peptidylprolyl isomerase A Ppia -0.65 NM_008907
Organic anion transporter 1 Slco1a1 -0.55 AY195868
Delta-aminolevulinate synthase 1 Alas1 0.98 NM_020559
Genes in bold – RT-PCR analysis is consistent with microarray data. Cyp3a41 probe cross-hybridizes with Cyp3a11.
Note. Three mice were used in this experiment.BMC Genomics 2008, 9:76 http://www.biomedcentral.com/1471-2164/9/76
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commonly done in microarray experiments. In the exper-
iment where mice were on a high-cholesterol diet, we
detected genes from cholesterol biosynthesis as down-reg-
ulated using both Sterolgene and Affymetrix arrays. How-
ever, with Sterolgene arrays, but not with Affymetrix, we
detected Cyp3a family and nuclear receptor Nr0b2 as up-
regulated and as previously described in [23,24]. In the
liver of mice treated with phenobarbital, we detected up-
regulation of the Cyp2b family using both Sterolgene and
Affymetrix arrays and as previously described in [21].
However, with Sterolgene arrays we additionally detect
genes from the Cyp3a family, Cyp2a4 and Alas1 as up-reg-
ulated and as previously described in [20,22]. Analysis of
Affymetrix data using the same p-value cut-off as for the
Sterolgene data showed two additional genes (Abca1,
Abcg5) as differentially expressed in cholesterol feeding
experiment, which were confirmed by another study [24]
where also Affymetrix arrays were used. However, we were
sill not able to confirm the up-regulation of Cyp3a11 and
Nr0b2. In phenobarbital experiment we were able to con-
firm the up-regulation of Alas1  and  Cyp2a4, but not
Cyp3a11.
Low agreement was observed between the Agilent and the
Sterolgene arrays in detecting changes in gene expression,
regardless of the selected p-value cut-off. In fasting and
TNF-α/fasted experiments we were able to detect changes
in expression of genes related to cholesterol homeostasis
and drug metabolism with Sterolgene arrays, but not with
Agilent arrays. In fasting experiment, we observed meta-
bolic adaptations to energy-shortage. Energy-consuming
processes as are cholesterol biosynthesis and drug metab-
Agreement of Sterolgene, Agilent and Affymetrix with RT-PCR data Figure 4
Agreement of Sterolgene, Agilent and Affymetrix with RT-PCR data. Venn diagrams illustrating genes differentially 
expressed by Sterolgene, Agilent, Affymetrix and RT-PCR measurements. Only genes tested by RT-PCR are shown. A: fasting 
experiment, B: TNF-α experiment, C: phenobarbital experiment, D: cholesterol feeding experiment. Differential expression 
was determined using two tailed Student's t-test at probability of type I error α = 0.05 for Sterolgene-Agilent comparison (A 
and B) and α = 0.1 for Sterolgene-Affymetrix comparison (C and D). Differential expression in RT-PCR experiments was 
determined using two tailed Student's t-test at probability of type error α = 0.05.
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olism are down-regulated. However, treatment with TNF-
α in combination with fasting reverses these adaptations
and up-regulation of cholesterol biosynthesis and down-
regulation of bile acids synthesis is observed. This results
in disrupted cholesterol homeostasis and higher levels of
cholesterol present in the mouse liver. All these findings
are in agreement with the hypothesis that pro-inflamma-
tory factors such as TNF-α are atherogenic [27].
Cross-platform comparisons using correlation analysis
showed correlations comparable to other cross-platform
comparison studies [12,17-19]. This result, together with
low correspondence in differential expression (especially
observed in Sterolgene-Agilent comparison) provides
strong justification for development of small-scale custom
arrays. As it turned out with Sterolgene data, small-scale
arrays are often more sensitive than whole-genome arrays
owing to the special care taken in designing probes.
Though we were able to show some important corre-
spondence between the Steroltalk and both commercial
platforms, our comparison has some limitations. First, we
were limited by the availability of samples, resulting in
low number of biological replicas used for comparisons. 
Table 2: Differentially expressed genes in the mouse liver after TNF-α treatment and fasting (Sterolgene v0 microarray). Differentially 
expressed genes in the mouse liver after TNF-α treatment/fasting as detected by the Sterolgene array (α = 0.05). Genes in bold – RT-
PCR analysis is consistent with microarray data.
Gene name and function Gene symbol Log2 ratio GeneBank Acc. No.
Cholesterol biosynthesis
Lanosterol 14α-demethylase Cyp51a1 1.35 BC031813
Sterol-C4-methyl oxidase-like Sc4mol 1.63 NM_025436
Bile acid biosynthesis
Sterol 12α-hydroxylase Cyp8b1 -1.82 NM_010012
Cytochrome P450 superfamily
Cytochrome P450, 2f2 Cyp2f2 -1.72 NM_007817
Cytochrome P450, 2j5 Cyp2j5 -0.68 NM_010007
Cytochrome P450, 3a25 Cyp3a25 -1.56 BC028855
Cholesterol side chain cleavage enzyme Cyp11a1 -0.30 NM_019779
Nuclear receptor superfamily
Testis receptor Nr2c1 -1.31 NM_011629
Glucocorticoid receptor Nr3c1 -0.97 NM_008173
Androgen receptor Nr3c4 -0.71 M37890
Other
Glyceraldehyde-3-phosphate dehydrogenase Gapd 0.53 NM_008084
Note. Three mice were used in this experiment.
Scatterplots of log2 ratios between Sterolgene, Agilent and Affymetrix Figure 5
Scatterplots of log2 ratios between Sterolgene, Agilent and Affymetrix. Scatterplots of log2 ratios of genes that are 
present in Agilent and Sterolgene arrays (A), and Affymetrix and Sterolgene arrays (B). Values from both experiments per-
formed for each cross-platform comparison were combined in a single plot.
 
 
 
 
 
 
 
 
 
 
 
 BMC Genomics 2008, 9:76 http://www.biomedcentral.com/1471-2164/9/76
Page 9 of 15
(page number not for citation purposes)
Table 3: Differentially expressed genes in the mouse liver after phenobarbital treatment (Sterolgene v0 microarray). Differentially 
expressed genes in the mouse liver after phenobarbital treatment as detected by the Sterolgene array (α = 0.1). 
Gene name and function Gene symbol Log2 ratio GeneBank Acc. No.
Cytochrome P450 superfamily – xenobiotic metabolism
Cytochrome P450, 1a2 Cyp1a2 0.57* NM_009993
Cytochrome P450, 2a4 Cyp2a4 1.89* BC011233
Cytochrome P450, 2b10 Cyp2b10 9.14* AK028103
Cytochrome P450, 2b13 Cyp2b13 9.94* NM_007813
Cytochrome P450, 2c40 Cyp2c40 0.79 NM_010004
Cytochrome P450, 2f2 Cyp2f2 -0.54* NM_007817
Cytochrome P450, 3a25 Cyp3a25 2.09* BC028855
Cytochrome P450, 3a41 Cyp3a41 3.24* NM_017396
Cytochrome P450 superfamily – endogene metabolism
Retionic acid hydrolase Cyp26a1 -0.72* NM_007811
Thromboxane A synthase 1 Cyp5a1 -1.11 NM_011539
Cytochrome P450, 7b1 Cyp7b1 -0.88 BC038810
Nuclear receptors superfamily
Constitutive androstane receptor Nr1i3 3.51* NM_009803
Testis receptor Nr2c1 -0.67* NM_011629
Glucocorticoid receptor Nr3c1 1.84* NM_008173
Transporters
Ileal sodium-dependent bile acid transporter Slc10a2 -1.55* NM_011388
Heme metabolism
Delta-aminolevulinate synthase 1 Alas1 3.36* NM_020559
Genes in bold – RT-PCR analysis is consistent with microarray data. 
*α = 0.05. Cyp3a41 and Cyp2b13 probes cross-hybridize with Cyp3a11 and Cyp2b10 respectively.
Note. Three mice were used in this experiment.
Table 4: Differentially expressed genes in the mouse liver after cholesterol feeding (Sterolgene v0 microarray). Differentially 
expressed genes in the mouse liver after cholesterol feeding as detected by the Sterolgene array (α = 0.1). 
Gene name and function Gene symbol Log2 ratio GeneBank Acc. No.
Cholesterol biosynthesis
Acetyl-Coenzyme A synthetase 2 Acas2 -2.35 NM_019811
Phosphomevalonate kinase Pmvk -1.18 NM_026784
Farnesyl diphosphate farnesyl transferase 1 Fdft1 -2.46 NM_010191
Squalene epoxidase Sqle -2.47* BC042781
Lanosterol 14α-demethylase Cyp51a1 -1.90 BC031813
NAD(P) dependent steroid dehydrogenase-like Nsdhl -2.06* BC019945
Bile acids biosynthesis
Cholesterol 7α-hydroxylase Cyp7a1 -1.44* NM_007824
Cytochrome P450, 7b1 Cyp7b1 -2.01* BC038810
Cholesterol transport
LDL receptor adaptor protein 1 Ldlrap1 0.76 NM_145554
Sterol carrier protein 2 Scp2 1.09* BC018384
Nuclear receptor superfamily
Small heterodimeric partner Nr0b2 0.94* NM_011850
Testis receptor Nr2c1 0.60* NM_011629
Glucocorticoid receptor Nr3c1 0.83* NM_008173
Cytochrome P450 superfamily – xenobiotic metabolism
Cytochrome P450, 2g1 Cyp2g1 1.09 NM_013809
Cytochrome P450, 3a41 Cyp3a41 1.92 NM_017396
Genes in bold – RT-PCR analysis is consistent with microarray data. 
*α = 0.05. Cyp3a41 probe cross-hybridizes with Cyp3a11.
Note. Two mice were used in this experiment.BMC Genomics 2008, 9:76 http://www.biomedcentral.com/1471-2164/9/76
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Additional samples and other diets/treatments may pro-
vide valuable information for the comparison and further
insight into the performance of Sterolgene array. Second,
we employed t-test based classification of differential
expression as this is usually the case in most biologically-
oriented studies. This may result in unstable variance
(noise) estimation [26]. Other less rigid classification
methods were developed, especially for microarray data
analysis where we are usually dealing with small number
of measurements. Although such methods might result in
better correspondence between the platforms, we still
decided to use a statistically-based method in order to
avoid the biases that alternative approaches often intro-
duce into results. Third, lab/platform effect, which can
often be higher than the biological effect [12,18,28,29]
must not be disregarded in the Sterolgene-Affymetrix
comparison. And most importantly, gene probes are not
sequence matched across the compared platforms, which
in combination with different approaches to probe design
and transcript variant detection can make a major contri-
bution to low agreement [30,31]. Finally, labeling step
and the choice of using amplification also contribute to
differences [32,33].
One of the obstacles in conducting the comparison, but
not the reason for low concordance, was the lack of anno-
tation for probes on the commercial platforms. With all
the tools available for microarray annotation there is still
a large portion of probes whose annotation remain
unknown and need a one by one search in the public data-
bases. Well annotated low density microarrays, such as is
Sterolgene, facilitate less demanding biological interpreta-
tion and confirmation of results. Another problem
exposed in early papers on cDNA microarrays is also a
high rate of incorrect clones in the cDNA libraries used for
their production [17,34]. For Sterolgene array we have
prepared our own cDNA library which we confirmed by
sequencing.
An important advantage of small arrays is in the design of
the probes. For whole-genome arrays, probes are designed
(semi)automatically with a limited attention dedicated to
each gene probe. With smaller arrays, more effort and a
priori knowledge is invested into their design, thus ena-
bling more accurate detection of changes in gene expres-
sion. The costs of producing and using small-scale
academic arrays are still low compared to commercial
ones. This is especially true for studies where a large
number of microarray experiments is planned, e.g. screen-
ing process in the development of new drugs.
Conclusion
We have demonstrated that the Sterolgene array is a novel
tool in studies of cholesterol homeostasis and drug
metabolism and can be used for more focused and cost-
effective systemic studies. Limited to our studies, we have
shown that its performance is comparable to the two com-
mercial platforms. Its application ranges from basic
research of how different factors influence these two bio-
logical processes to testing effects of new cholesterol low-
ering drugs. It is a tool which can be easily adjusted to
novel research needs and interests. We are constantly
improving the array with new genes and probes; we have
recently developed the third version of the array, which
contains an expanded list of genes involved in atherogen-
esis, circadian rhythm, inflammation and metabolism of
carbohydrates and lipids, together with its human version
consisting of human counterparts of most of the genes,
thus allowing analysis of clinical samples.
Changes in cholesterol homeostasis and drug metabolism  caused by different factors in mouse liver Figure 6
Changes in cholesterol homeostasis and drug metab-
olism caused by different factors in mouse liver. With 
Sterolgene array we successfully detected all changes in cho-
lesterol homeostasis and drug metabolism caused by high-
cholesterol diet, fasting, TNF-α, and phenobarbital (PB) 
treatment (solid arrows). With Agilent array (G4104A) we 
detected none of the changes caused by the inflammatory 
cytokine TNF-α and fasting (crosses). With Affymetrix 
MOE430A GeneChip we detected only down-regulation of 
the cholesterol biosynthesis by the high-cholesterol diet and 
induction of the Cyp2b family by the phenobarbital treatment 
(dashed arrows), but not the up-regulation of Cyp3a11 by 
high-cholesterol diet and up-regulation of Cyp3a family and 
Alas1 by phenobarbital treatment. In all experiments, two 
tailed Student's t-test was used for classification of differen-
tially expressed genes.
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Methods
Chemicals
All chemicals were purchased from Sigma (St Louis, MI,
USA) if not stated otherwise.
Mouse experiments and sample preparation
In the TNF-α (tumor necrosis factor alpha) and fasting
experiments male mice C57BL/6 (Harlan, Italy) age
between 10 and 12 weeks were housed in normal light-
cycle room, maintained on standard rodent chow, and
were allowed water and food ad libitum [15]. Three groups
of mice, 5–8 animals per group, were injected i.v at the
same time point either with vehicle (saline) or with
human recombinant TNF-α 30 μg/animal in saline (a gift
from V. Menart, Lek Pharmaceuticals d.d.) and food was
withdrawn, except for the control group. After 20 h mice
were sacrificed using CO2 suffocation. Total RNA was iso-
lated from liver using TRI-reagent (Sigma, St Louis, MI,
USA) and purified by RNeasy Mini Kit (Qiagen GmBH,
Hilden, Germany) according to the manufacturer's proto-
cols.
In phenobarbital treatment and cholesterol feeding exper-
iments male mice C57BL/6 (RCC, Ittingen, Switzerland)
age between 9 and 11 weeks were maintained in a 12-
hour light/12-hour dark cycle and fed ad libitum standard
rodent chow diet or the same diet supplemented with 1%
(w/w) cholesterol (Provimi Kliba SA, Kaiseraugst, CH).
Mice were divided in three groups, 8 animals per group:
the control group which was injected i.p.  vehicle (5%
DMSO-corn oil) and maintained on standard diet; the
cholesterol group which was maintained on cholesterol
diet for week prior injection and injected i.p. vehicle; and
the phenobarbital group which was maintained on stand-
ard diet and injected i.p. with 50 mg/kg phenobarbital
sodium in a 5% DMSO-corn oil. After 10 hours, animals
were sacrificed using CO2 suffocation. The livers were
snap-frozen in liquid nitrogen, total RNA was isolated
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer protocol and purified by
RNeasy Mini Kit (Qiagen GmBH, Hilden, Germany). The
total RNAs of two animals were pooled in equal amounts
resulting in four pools per group. Quality and purity of
total RNAs from both studies were checked using the RNA
6000 Nano LabChip Kit on Agilent 2100 Bioanalyzator
(Agilent Technologies, Pato Alto, CA, USA). All animal
experiments followed the Amsterdam Protocol on Animal
Protection and Welfare and were approved by the local
ethics committees.
cDNA microarray production
For 95 selected genes cDNA microarray probes of a similar
length (400 – 500 bp), melting temperature and located
less than 1500 bp from the polyA tail were designed using
ProbeWIZ software [35]. Three probes of firefly luciferase
in sequential order from the 5'-end to the polyA tail have
been designed as controls of the reverse transcriptase reac-
tion and as normalization controls. Chloramphenicol
acetyltransferase (CAT) and Renilla luciferase gene probes
were designed as negative controls. For housekeeping
genes two to three probes were designed enabling control
of RNA degradation rate. PCR products were prepared and
cloned using the Qiagen PCR Cloning kit (Qiagen GmBH,
Hilden, Germany). Plasmids were sequenced to verify the
correct insert sequence. From these plasmids PCR prod-
ucts were amplified (Qbiogene, Morgan Irvine, CA, USA)
and purified using the QIAquick 96 PCR BioRobot purifi-
cation kit (Qiagen GmBH, Hilden, Germany). PCR prod-
ucts were dried and dissolved in 50% formamide and 1%
CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-1-
propane sulfonate) spotting buffer in final 200 ng/μl con-
centration. DNAs were spotted on GAPS II-coated slides
(Corning Inc. Corning, NY, USA) using a GeneTAC G3
robot (Genomic Solutions, Huntington, UK) in a control-
led environment (25°C to 26°C and 25–29% humidity).
Each PCR product was spotted in triplicates in two blocks
yielding 6 replicas. Firefly luciferase probes were spotted
in each block. Commercial "spike in controls" ArrayCon-
trol Spikes (Ambion, Austin, TX, USA) were also spotted,
two in each block. After spotting slides were dried for 8
hours at room temperature, protected from light. The
DNA was fixed by UV cross-linking at 250 mJ/cm2 (Hoefer
UVC500, Amersham Pharmacia Biotech, San Francisco,
CA, USA). Slides were stored in a dry and dark place.
Probe labeling and hybridizations
In TNF-α/fasted and fasting experiments, individual sam-
ples from fasted and TNF-α-treated groups were hybrid-
ized versus a reference pool of samples from normal-fed
control group using Sterolgene (3 biological replicas) and
Agilent arrays (2 biological replicas, identical to those
used in Sterolgene hybridizations). The hybridizations
were performed in a single laboratory according to the rec-
ommended protocols.
In phenobarbital and high cholesterol feeding experi-
ments, samples from 8 mice were pooled by two into 4
pools for each control, cholesterol fed and phenobarbital
treated group. All 4 pools from each group were hybrid-
ized to Affymetrix GeneChips. 2–3 pools, identical to
those used in Affymetrix hybridizations, were hybridized
together with a reference pool (pool of all samples) to
Sterolgene arrays. Hybridizations of each of the platforms
were performed in two different laboratories according to
the recommended protocols.
In Sterolgene experiments, 10 μg of total RNA was used
for labeling using Agilent Fluorescent Direct Label Kit
(Agilent Technologies, Pato Alto, CA, USA) according to
the manufacturer's protocol. Before labeling spike RNAsBMC Genomics 2008, 9:76 http://www.biomedcentral.com/1471-2164/9/76
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were added to the total RNA in following quantities: 500
pg of Firefly luciferase mRNA (Promega, Madison, WI,
USA); and one of the two mixes (reference mix and sam-
ple mix) of 8 RNAs from ArrayControl Spikes (Ambion,
Austin, TX, USA). The reference spike mix was a mixture of
500 pg of each RNA. The sample spike mix was a mixture
of RNAs ranging from 100 pg to 1500 pg. In the TNF-α
and fasting experiment, the control group was labeled
with Cy3 (PerkinElmer Life Sciences, Boston, MA, USA),
the fasted and the TNF-α treated groups were labeled with
Cy5 (PerkinElmer Life Sciences, Boston, MA, USA). In the
phenobarbital and cholesterol experiment the control,
cholesterol and phenobarbital groups were labeled with
Cy5 and the reference was labeled with Cy3. Sterolgene
slides were washed before hybridization at room temper-
ature for 5 min in 2 × SSC and 0.1%SDS, 3 min in 0.2 ×
SSC and 2 min in MilliQ water and dried by centrifuga-
tion. Samples were denatured and hybridized in 3 × SSC
and 0.2% SDS hybridization buffer at 65°C for 16 hours
using humidified hybridization chambers (HybCham-
bers, GeneMachines, San Carlos, CA, USA). After hybridi-
zation slides were washed at room temperature for 5 min
in 2 × SSC and 0.5% SDS, followed by 5 min in 0.5 × SSC,
then 5 min in 0.05 × SSC and dried by centrifugation.
Slides were scanned using a Tecan LS200 scanner (Tecan
Group Ltd., Maennedorf, Switzerland).
In Agilent experiments, 10 μg of total RNA was used for
labeling by Agilent Fluorescent Direct Label Kit (Agilent
Technologies, Pato Alto, CA, USA). Preparation of sam-
ples, hybridization and washing protocols were done
according to Mouse cDNA Microarray Kit (Agilent Tech-
nologies, Santa Clara, CA, USA) using the mouse Agilent
cDNA microarrays (G4104A). The control group was
labeled with Cy3, the fasted and the TNF-α treated group
were labeled with Cy5. Hybridizations were performed
using hybridization chambers (HybChambers, GeneMa-
chines, San Carlos, CA, USA) and slides scanned by Tecan
LS200 scanner (Tecan Group Ltd., Maennedorf, Switzer-
land).
In Affymetrix experiments, total RNA was analyzed by the
MOE430A GeneChip (Affymetrix, Santa Clara, CA, USA)
according to manufacturer's recommendations and slides
scanned by a laser scanner (Affymetrix, Santa Clara, CA,
USA) as described in [36].
Data normalization and analysis
Images of Sterolgene arrays were analyzed by Array-Pro
Analyzer 4.5 (Media Cybernetics, Bethesda, MD, USA).
The median feature and local background intensities were
extracted together with the estimates of their standard
deviation. Only features with foreground to background
ratio higher than 1.5 and coefficient of variation (CV,
ratio between standard deviation of the background and
the median feature intensity) lower than 0.5 in both chan-
nels were used for further analysis. Log2 ratios were nor-
malized using LOWESS fit [37] to spike in control RNAs
according to their average intensity. For normalization,
two types of spike in controls were used: custom-made
Firefly luciferase (348 such probes per array) and com-
mercial ArrayControl Spikes (Ambion, Austin, TX, USA)
(96 such probes per array). Ambion spike in RNAs were
added to each sample RNAs in the following concentra-
tions: 1:5, 1:2, 1:1, 2:1 and 3:1. Data from Ambion spike
in controls were adjusted prior to fit of normalization
curve by subtracting log2(1/5), log2(1/2), log2(2) and
log2(3) from the log2  ratios of measured intensities
according to the concentrations (Figure 3C). In phenobar-
bital and cholesterol-feeding experiments data were
standardized (median-centered and scaled by median
absolute deviation) in order to reduce inter-array variabil-
ity. Mean was used to average replicated microarray meas-
urements. Data normalization and standardization was
done in Orange software [13].
Images of Agilent microarrays were analyzed using Array-
Pro Analyzer 4.5 (Media Cybernetics, Bethesda, MD,
USA). Features, with CV > 0.39, were filtered out and data
were normalized using LOWESS fit to all genes according
to their average intensity [38]. Filtration and normaliza-
tion was done in BASE software [39].
Affymetrix data were normalized by the Robust Multichip
Average (RMA) algorithm as described [40]. After transfor-
mation to non-logarithmic data, the expression estimates
were scaled to the average expression levels in the control
group analyzed using GeneSpring software (Silicon
Genetics, Redwood, USA).
Classification of differentially expressed genes was done
in Orange using two tailed Student's t-test for independ-
ent samples. Between the platforms genes were matched
by unigene or refseq codes, or by gene symbols. Pearson's
product moment correlation coefficients were calculated
and scatterplots produced in SPSS 14.0. All data have been
submitted to GEO (Gene expression omnibus) under
accession codes: GSE6271 (Affymetrix data), GSE6317
(Agilent data), GSE6447 (Sterolgene phenobarbital and
high-cholesterol diet data), and GSE6423 (Sterolgene fast-
ing and inflammation data).
Real-time polymerase chain reaction (RT-PCR)
RT-PCR analyses were performed in triplicates on pools of
3 mice from each group in TNF-α and fasting experiments,
and on 4 biological replicas in phenobarbital and high-
cholesterol diet experiments. In TNF-α and fasting experi-
ments 1 μg of total RNA was reverse-transcribed using
Superscript™ II or III reverse transcriptase (Invitrogen,
Carlsbad, CA, USA). Analyses were done using Platinum®BMC Genomics 2008, 9:76 http://www.biomedcentral.com/1471-2164/9/76
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SYBR® Green qPCR SuperMix-UDG (Invitrogen, Carlsbad,
CA, USA), except in case of Sc4mol  where Assay-on-
demand from Applied Biosystems was used, and were per-
formed on Applied Biosystems ABI PRISM 7900 HT or
7500 (PE Applied Biosystems, Foster City, CA, USA)
according to the manufacturer's protocol. In phenobarbi-
tal and high-cholesterol diet experiments 1 μg of total
RNA was reverse-transcribed using MMLV reverse tran-
scriptase (Roche Molecular Biochemicals, Rotkreuz, Swit-
zerland). Analyses (for transcripts Cyp3a11, Cyp2b10,
Alas1) were done using the TaqMan PCR Core Reagent Kit
(PE Applied Biosystems, Rotkreuz, Switzerland), and per-
formed on ABI PRISM 7700 Sequence Detection System
(PE Applied Biosystems, Rotkreuz, Switzerland) accord-
ing to the manufacturer's protocol. Additional analyses
(for transcript Scap, Apoa1, Car, Cyp7a1, Cyp1a2, Scarb1,
Ppara, Cyp26a1) were done using Platinum® SYBR® Green
qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA)
and 7500 (PE Applied Biosystems, Foster City, CA, USA)
according to the manufacturer's protocol. Relative tran-
script levels were determined using the comparative Ct
(cycle threshold) method or using 2-ddCt values [41]. Inter-
nal control used in the first set of experiments is 18s and
in the second set Gapdh. Statistical significance was deter-
mined by two tailed Student's t-test (α = 0.05). Primer
sequences are provided in additional material (Additional
file 10).
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